Atea anticipates Phase III C-BEYOND midyear and C-FORWARD year-end readouts while projecting cash runway through 2027

"With 2 pivotal Phase III top line readouts for our global Phase III HCV program ahead of us, 2026 will be a catalyst-rich year for Atea" (Founder, Chairman, CEO & President Jean-Pierre Sommadossi).

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026C-FORWARD ...
Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Seeking Alpha

Atea targets mid-2026 Phase III HCV results while expanding hepatitis pipeline and maintaining $329.3M cash runway

Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...
Nasdaq

Atea Pharmaceuticals Launches Phase 3 C-FORWARD Trial for HCV Treatment Regimen Combining Bemnifosbuvir and Ruzasvir

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...
Medscape

Drop in HIV/HCV Coinfections After Nationwide HCV Program

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...